Phosphorylation of SREBP1c competes with its ubiquitination, exacerbating hepatic steatosis, whereas the pharmacological inhibition of phosphorylation significantly downregulates SREBP1c expression, ameliorating lipid deposition [70]. The gene discussed is SREBF1; the disease is fatty liver disease.